A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy Journal Article


Authors: Xu, H.; Buhtoiarov, I. N.; Guo, H.; Cheung, N. K. V.
Article Title: A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy
Abstract: The role of T cells in controlling human cancers is well known. Their success requires continued persistence in vivo and efficient trafficking to tumor sites, requirements shared by other effectors such as Natural Killer (NK) cells. To date, cytokine IL2 remains the only clinically approved cytokine therapy available to expand, maintain, and activate these effector lymphoid cells, but toxicities can be severe. Cytokine IL15 offers similar T cell proliferation and activation properties, but without the unwanted side-effects seen with IL2. Several IL15-cytokine fusion proteins have been developed to improve their in vivo function, typically exploiting the IL15Rα to complex with IL15, to extend serum half-life and increase affinity for IL15β receptor on immune cells. Here we describe a novel IL15 complex incorporating the full-length IL15Rα to complex with wild type IL15 to form spontaneous trimers of dimers (6 IL15 + 6 IL15Rα) during co-expression, resulting in a substantial increase in serum half-life and enhancement of in vivo cytokine effect on IgG or T cell engaging antibody-dependent cell-mediated cytotoxicities, when compared to alternative strategies. © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Keywords: immunotherapy; bispecific antibody; hu3f8; il15; il15rα
Journal Title: OncoImmunology
Volume: 10
Issue: 1
ISSN: 2162-4011
Publisher: Landes Bioscience  
Date Published: 2021-01-01
Start Page: 1893500
Language: English
DOI: 10.1080/2162402x.2021.1893500
PROVIDER: scopus
PMCID: PMC7954438
PUBMED: 33763293
DOI/URL:
Notes: Article -- Export Date: 1 April 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Nai-Kong Cheung
    648 Cheung
  2. Hong Xu
    53 Xu
  3. Hong-Fen Guo
    73 Guo